BioNTech (BNTX) PT Raised to $62 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BioNTech SE (BNTX) Reports Q2 Loss of $0.38
August 11, 2020 6:05 AM EDTBioNTech SE (NASDAQ: BNTX) reported Q2 EPS of ($0.38), versus ($0.24) reported last year.
Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was 41.8 million for the three months ended June 30, 2020, compared to 25.8 million for the three months ended June 30, 2019. For the period of six months ended June 30, 2020, total revenue was 69.4 million, compared to 51.9 million for the comparative prior year period. The revenue from collaboration agreements overall increased due to the recognition of revenue from our new collaboration agreements signed with Pfizer and Fosun Pharma as part of the Companys BNT162 vaccine program against... More
